PMID- 30729696
OWN - NLM
STAT- MEDLINE
DCOM- 20190903
LR  - 20190903
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 22
IP  - 4
DP  - 2019 Apr
TI  - HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a 
      Lebanese population: Results from a nationwide study.
PG  - 708-714
LID - 10.1111/1756-185X.13487 [doi]
AB  - AIM: To calculate the prevalence of human leukocyte antigen (HLA)-B27 in axial 
      spondyloarthritis patients (axSpA) compared to blood donors (BD) in Lebanon, to 
      identify the clinical and radiological findings associated with HLA-B27 and to 
      estimate the proportion of patients fulfilling the clinical arm of the Assessment 
      of the Spondyloarthritis International Association (ASAS) criteria. METHOD: 
      Consecutive Lebanese adult axSpA patients fulfilling the ASAS classification 
      criteria were included from 12 rheumatology clinics across Lebanon. BD served as 
      controls. A binary logistic regression was used to study the association between 
      HLA-B27 and the disease features. RESULTS: A total of 247 individuals were 
      included (141 axSpA patients and 106 BD). The prevalence of HLA-B27 was 3.8% in 
      BD and 41.1% in axSpA. Overall, 39.7% of the axSpA patients fulfilled the 
      clinical arm of the ASAS classification criteria. Sensitivity of HLA-B27 for 
      axSpA was 41.1%, specificity was 96.2%, positive predictive value was 93.6%, and 
      negative predictive value was 55.13%. Positive likelihood ratio (LR) was 10.9 and 
      negative LR was 1.63. We found a positive association of HLA-B27 with family 
      history of SpA and psoriasis. CONCLUSION: Our study confirmed a low prevalence of 
      HLA-B27 in axSpA patients and BD in this Lebanese population, However, we found a 
      high specificity and positive LR, as well as the same number of axSpA patients 
      fulfilling the clinical arm of the ASAS criteria as in European studies. HLA-B27 
      is therefore valuable for identification of axSpA in Lebanese patients despite 
      the overall low prevalence in this population. Our results may guide future 
      evaluations the role of HLA-B27 in planning local referral strategies.
CI  - (c) 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Ziade, Nelly
AU  - Ziade N
AUID- ORCID: 0000-0002-4479-7678
AD  - Rheumatology Department, Saint-Joseph University, Beirut, Lebanon.
AD  - Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
FAU - Abi Karam, Ghada
AU  - Abi Karam G
AD  - Rheumatology Department, Saint-Joseph University, Beirut, Lebanon.
AD  - Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
FAU - Merheb, Georges
AU  - Merheb G
AD  - Rheumatology Department, Holy Spirit University, Kaslik, Lebanon.
AD  - Rheumatology Department, Notre-Dame des Secours University, Lebanon.
FAU - Mallak, Iyad
AU  - Mallak I
AD  - Radiology Department, Hotel-Dieu de France, Beirut, Lebanon.
FAU - Irani, Laure
AU  - Irani L
AD  - Lebanese University Hospital, Beirut, Lebanon.
AD  - Rizk University Medical Center, Beirut, Lebanon.
FAU - Alam, Elie
AU  - Alam E
AD  - Levant Hospital, Sin-el-Fil, Lebanon.
FAU - Messaykeh, Jamil
AU  - Messaykeh J
AD  - Monla Hospital, Tripoli, Lebanon.
FAU - Menassa, Jeanine
AU  - Menassa J
AD  - Lebanese University Hospital, Beirut, Lebanon.
AD  - Geitawi Hospital, Beirut, Lebanon.
FAU - Mroue', Kamel
AU  - Mroue' K
AD  - Al Zahra University Hospital, Beirut, Lebanon.
FAU - Uthman, Imad
AU  - Uthman I
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Masri, Abdel Fattah
AU  - Masri AF
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
FAU - Ghorra, Pierre
AU  - Ghorra P
AD  - Blood Transfusion Center, Hotel-Dieu de France, Beirut, Lebanon.
FAU - Witte, Torsten
AU  - Witte T
AD  - Medical University, Hannover, Germany.
FAU - Baraliakos, Xenofon
AU  - Baraliakos X
AD  - Rheumazentrum Ruhrgebiet, Herne, Germany.
AD  - Ruhr-Universitat Bochum, Bochum, Germany.
LA  - eng
GR  - AbbVie Deutschland GmbH & Co. KG/
PT  - Journal Article
DEP - 20190206
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (HLA-B27 Antigen)
SB  - IM
MH  - Adult
MH  - *Blood Donors
MH  - Case-Control Studies
MH  - Female
MH  - *Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - HLA-B27 Antigen/*genetics/immunology
MH  - Humans
MH  - Lebanon/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Molecular Epidemiology
MH  - Phenotype
MH  - Prevalence
MH  - Risk Factors
MH  - Spondylarthritis/diagnosis/epidemiology/*genetics/immunology
MH  - Young Adult
OTO - NOTNLM
OT  - ankylosing spondylitis
OT  - biomarkers
OT  - diagnostic tests
OT  - epidemiology
OT  - genetics
EDAT- 2019/02/08 06:00
MHDA- 2019/09/04 06:00
CRDT- 2019/02/08 06:00
PHST- 2018/05/13 00:00 [received]
PHST- 2018/12/31 00:00 [revised]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/02/08 06:00 [pubmed]
PHST- 2019/09/04 06:00 [medline]
PHST- 2019/02/08 06:00 [entrez]
AID - 10.1111/1756-185X.13487 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2019 Apr;22(4):708-714. doi: 10.1111/1756-185X.13487. Epub 2019 
      Feb 6.